Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution
Daptomycin, is a cyclic lipopeptide antibiotic with potent bactericidal activity against most Gram-positive organisms including vancomycin resistant enterococci, methicillin-resistant staphylococci, and “heterodrug-resistant” glycopeptide-resistant Staphylococcus aureus [1]. Daptomycin is indicated for the treatment of complicated skin and soft tissue infections (cSSTIs) caused by susceptible strains of Gram-positive microorganisms and is approved for the treatment of Staphylococcus aureus blo odstream infections and right-sided infective endocarditis (IE).
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Alicia Galar, Patricia Mu ñoz, Maricela Valerio, Emilia Cercenado, Xandra García-González, Almudena Burillo, Mar Sánchez-Somolinos, Miriam Juárez, Eduardo Verde, Emilio Bouza Source Type: research
More News: Cubicin | Drugs & Pharmacology | Endocarditis | Infective Endocarditis | MRSA | Skin | Staphylococcus Aureus